Please login to the form below

Not currently logged in
Email:
Password:

armodafinil

This page shows the latest armodafinil news and features for those working in and with pharma, biotech and healthcare.

Teva halts development of Nuvigil in bipolar disorder

Teva halts development of Nuvigil in bipolar disorder

The Israel-based pharma company said that Nuvigil (armodafinil) failed to demonstrate it was significantly more effective than placebo during a phase III trial investigating its use as an adjunct therapy ... While this study demonstrated a numerical

Latest news

  • Teva suffers setback as Nuvigil fails late-stage trial Teva suffers setback as Nuvigil fails late-stage trial

    Nuvigil (armodafinil) did not show a significant improvement over placebo when added on to therapy with mood stabilisers or atypical antipsychotics in the study, which involved patients with major depression associated

  • Cephalon jet lag application rejected

    Cephalon has dropped its bid to get its sleep disorder drug Nuvigil (armodafinil) approved as a treatment for jet lag after the marketing application was rejected by the US Food and

  • State of mind

    Armodafinil (Nuvigil, Cephalon) is currently being investigated as a therapy for bipolar disorders. ... A phase II trial is currently underway to assess the efficacy of armodafinil in patients with bipolar depression.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics